Home
Search
SurgiMabSurgiMab
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Investors
    • Partners
  • News & Events
  • Contact us
  • Français
SurgiMab announces SGM-101 publication in Surgical Oncology
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Investors
    • Partners
  • News & Events
  • Contact us
  • Français
EnglishEnglishFrançaisFrançais

SurgiMab announces SGM-101 publication in Surgical Oncology

SurgiMab > News & Events > News > SurgiMab announces SGM-101 publication in Surgical Oncology
Surgical Oncology
29 March 2017 Administrateur SurgiMab0

SurgiMab is happy to announce the publication of its manuscript entitled “SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery” in the peer-reviewed journal Surgical Oncology. This paper describes the Near-Infrared fluorescent CEA-targeting molecule developped by SurgiMab as well as pre-clinical tumor-targeting results in murine tumor models.

Please click on the following link to get a pdf version of the article. Surg Oncol 26 153 Gutowski M Framery B

Previous Post
SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.
Next Post
SurgiMab is an Entrepreneur Sponsor of the first Boston-Paris Biotechnology Summit

Recent Posts

  • SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
  • SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
  • SGM-101 Clinical Results in Colorectal Cancer published in the Lancet Gastroenterology & Hepatology
  • SurgiMab sponsors the “Molecular Guided Surgery” conference of the SPIE Photonics West meeting in San Francisco 27-28 January 2018
  • SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial
SurgiMab
Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

  • SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
  • SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
Home . Legal & credits
Copyright © 2019 SurgiMab. Website by B-to-B Design